KAT6A and ovarian cancer: Here, KAT6A LLPS also enhanced the subsequent DDR capacity by impairing PARP1 trapping and reducing PARP1‐DNA complexes, which attenuated the cytotoxic effects of PARP1 trapping, leading to resistance to PARP inhibitors in ovarian cancer cells.